Virus mutations and public scrutiny will make it tough for firms to cash in on a cure
New fund supports development of cancer diagnostics and treatments and seeks to identify breakthrough innovations
Luxembourg-domiciled Sicav will target long-term growth in the fast-growing biotechnology sector
A raft of disruptive technology funds are now available in Europe. How should selectors navigate this complex new area?
The biotech sector is going through a renaissance as innovation takes off according to one successful fund manager, but data shows that performance over the last three years has been far less than stellar.
In the decade since the financial crisis, pharmaceuticals, healthcare and bioscience-focused funds have significantly outperformed the MSCI World index.
The biotechnology sector is on the cusp of potentially revolutionary developments, says disruptive opportunities specialist Wesley Lebeau, but the journey is not without pitfalls.
As the dust (hopefully soon) starts to settle on last week’s market carnage, investors are out pointing fingers at the biggest losers, and speculating on whether they could be tomorrow’s big winners.